Navigation Links
Measuring hormone cuts antibiotic use in half in pneumonia patients

Measuring a hormone in the blood can help doctors greatly reduce the number of days pneumonia patients have to take antibiotics to cure their infection, according to a study to be presented at the American Thoracic Society International Conference on May 24.

In the study, pneumonia patients whose level of the hormone procalcitonin was measured during the course of their illness took antibiotics an average of 6 days, compared with 12 days for patients whose procalcitonin levels were not measured. Fifteen percent of patients whose hormone levels were measured did not have to take antibiotics at all, said study co-author Michael Tamm, M.D., Chief of Pulmonary Medicine and Pulmonary Cell Research at University Hospital in Basel, Switzerland.

"Because of concerns about antibiotic resistance, as well as the cost of antibiotics, it's always better to give fewer antibiotics," Prof. Tamm said.

Many cases of community-acquired pneumonia are caused by bacteria, which require treatment with antibiotics, but some cases are viral, which get better without antibiotics. But doctors don't like to delay treatment in order to wait for lab results to tell them whether a patient's pneumonia is bacterial or viral, so they start all patients on antibiotics, Dr. Tamm said. "Once the treatment is started, it is usually continued for 10 to 14 days, because nobody knows when you can stop without a risk for the patient," he said.

Because levels of procalcitonin have been found to be elevated in patients with bacterial infection but not viral infection or other inflammatory diseases, Dr. Tamm and colleagues decided to study whether measuring levels of the hormone could eliminate or reduce antibiotic use in patients with bacterial pneumonia. Results of the blood test that measures procalcitonin levels can be obtained in only one hour, he said.

They studied more than 300 patients with community-acquired pneumonia (pneumonia that is not caught while a patient is in the hospital), and randomly divided them into two groups. Once group was given the standard antibiotic treatment, while the other was first tested for procalcitonin levels. Fifteen percent of those patients had very low procalcitonin levels, and were presumed to have viral pneumonia; they were not given antibiotics. The remaining 85% had high levels and were started on antibiotics. The researchers measured their procalcitonin levels four, six and eight days later, and discontinued their antibiotics if their levels were low.

Patients in the procalcitonin group who started on antibiotic treatment were able to stop after an average of six days. Their course of illness was similar to those patients who received a full course of antibiotics, in terms of their recovery and number of days spent in the hospital. "We showed we were able to cut the number of days patients were on antibiotics in half, without compromising their outcome," Dr. Tamm said.


Source:American Thoracic Society

Related biology news :

1. Measuring the impact of post-genomics on Mediterranean populations
2. Measuring Enzymes At End Of Cancer Pathway Predicts Outcome Of Tarceva, Taxol
3. Measuring hidden parasites in falciparum malaria
4. Measuring artery repair cells could become new heart disease test
5. Female sex hormones play a vital role in defense against sexually transmitted diseases
6. Deficiency of growth hormone and IGF-1 reduces cancer and kidney disease, but creates other problems
7. Alcohol consumption disrupts breastfeeding hormones
8. VCU study shows hormone-like molecule kills cells that cause inflammation in allergic disease
9. University of Nevada, Reno research team discovers hormone that causes malaria mosquito to urinate
10. Penguin chicks exposed to human visitors experience spike in stress hormone
11. Suppressing growth hormone in early adulthood may prevent cancer
Post Your Comments:

(Date:11/10/2015)... Nov. 10, 2015  In this report, ... basis of product, type, application, disease indication, ... this report are consumables, services, software. The ... safety biomarkers, efficacy biomarkers, and validation biomarkers. ... are diagnostics development, drug discovery and development, ...
(Date:11/4/2015)... 4, 2015 --> ... published by Transparency Market Research "Home Security Solutions Market - ... 2015 - 2022", the global home security solutions market is expected ... 2022. The market is estimated to expand at a ... to 2022. Rising security needs among customers at homes, ...
(Date:10/29/2015)... Oct. 29, 2015 Daon, a global leader ... has released a new version of its IdentityX ... North America have already installed IdentityX ... includes a FIDO UAF certified server component ... to activate FIDO features. These customers include some of ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... 2015 Cepheid (NASDAQ: CPHD ) today ... following conference, and invited investors to participate via webcast. ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern Time ... New York, NY      Tuesday, December 1, 2015 ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... event of the year and one of the premier annual events for pharmaceutical ... ran from 8–11 November 2015, where ISPE hosted the largest number of attendees ...
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software ... events in five states to develop and pitch their BIG ideas to improve health ... state are competing for votes to win the title of SAP's Teen Innovator, an ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
Breaking Biology Technology: